Zoladex (Prostate Cancer) - Forecast and Market Analysis to 2022


#163783

45pages

GlobalData

$ 6995

In Stock

Zoladex (Prostate Cancer) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Zoladex (Prostate Cancer) - Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

AstraZeneca’s Zoladex is a subcutaneous implant that delivers goserelin acetate, a synthetic analog of LHRH. It is classified as an LHRH receptor agonist (Zoladex Prescribing Information, 2010). It binds to the LHRH receptor and prevents the pituitary gland from secreting luteinizing hormone. 

Without luteinizing hormone, the testes do not produce testosterone. Since testosterone is known to drive the progression of prostate cancer, LHRH analogs are commonly used in ADT regimens. Zoladex is commonly used to control hormone-sensitive prostate cancer, and to maintain castrate levels of testosterone in patients with CRPC.

Scope
  • Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Zoladex including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Zoladex for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia 
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Zoladex performance 
  • Obtain sales forecast for Zoladex from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)
Table of Contents

1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
2.3 Upcoming Related Reports 9

3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 10
3.1.3 Prognosis 11
3.1.4 Quality of Life 12
3.2 Symptoms 12

4 Disease Management 13
4.1 Diagnosis and Referral Overview 13
4.2 Treatment Overview 15
4.2.1 Conservative Management Strategies 19
4.2.2 Localized Treatments 20
4.2.3 Hormone Therapy 21
4.2.4 Drug Therapies 23

5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26

6 Zoladex (goserelin acetate) 29
6.1 Overview 29
6.2 Efficacy 30
6.3 Safety 30
6.4 SWOT Analysis 31
6.5 Forecast 32

7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 37
7.3 Methodology 39
7.4 Forecasting Methodology 39
7.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 39
7.4.2 Percent Drug-treated Patients 40
7.4.3 Percent Hormone Therapy-Treated Patients 40
7.4.4 General Pricing Assumptions 40
7.4.5 Individual Drug Assumptions 42
7.4.6 Generic Erosion 43
7.5 Physicians and Specialists Included in This Study 43
7.6 Survey of Prescribing Physicians 43
7.7 About the Authors 44
7.7.1 Authors 44
7.7.2 Global Head of Healthcare 44
7.8 About GlobalData 45
7.9 Contact Us 45
7.10 Disclaimer 45

Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 11
Table 2: Global Variations in Recommendations on Routine PSA Screening 13
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 16
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 18
Table 5: Leading Treatments for Prostate Cancer, 2012 28
Table 6: Product Profile - Zoladex 29
Table 7: Zoladex SWOT Analysis, 2012 31
Table 8: Global Sales Forecasts ($m) for Zoladex, 2012-2022 32
Table 9: Physicians Surveyed, By Country 43
Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 17